Pure Global
NCT06366932

Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models

Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Multiomic Predictive Models of Treatment Response (DermAtOmics-II)
Instituto de Investigación Hospital Universitario La Paz·Phase 4·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Atopic Dermatitis
Drug/Device/Intervention
Second-line systemic treatment
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Instituto de Investigación Hospital Universitario La Paz
Location
Madrid, Spain
Timeline & enrollment
Phase
Phase 4
Start date
Sep 25, 2023
End date
Sep 01, 2025
Enrollment
150 participants
Primary outcome

Percentage of patients with primary non-response to second-line treatment.

Summary

This is a low-intervention phase IV trial. The main objective is to optimize the treatment of
 patients with moderate-severe atopic dermatitis that require systemic treatment after
 failure, intolerance or contraindication to cyclosporine.

ICD-10 classifications
Atopic dermatitisAtopic dermatitis, unspecifiedOther atopic dermatitisAcute atopic conjunctivitisAllergic contact dermatitis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06366932
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06366932 through Pure Global AI's free database. This Phase 4 trial is sponsored by Instituto de Investigación Hospital Universitario La Paz and is currently Recruiting. The study focuses on Atopic Dermatitis. Target enrollment is 150 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.